Applications of nanotech may provide bioavailability

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/bogdanhoda)
(Image: Getty/bogdanhoda)

Related tags: bioavailability, Nanotechnology, Drugs, CDMO, Early phase

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drug’s chance of success, according to Ascendia CEO.

At Interphex next week, members of Ascendia, a contract development and manufacturing organization (CDMO), will present a talk on the applications of nanotechnologies for drug development.

The CDMO specializes in the manufacture and development of drugs for preclinical, and early phase human studies, using nanotechnologies, like nano-emulsion and nano-particle engineering, to produce the most effective method of drug delivery for poorly water-soluble models.

Bioavailability, in particular, is one component of drug development that Ascendia believes can benefit from the innovations and applications of nanotechnologies.

Jim Huang, founder and CEO of Ascendia, told us that nanotechnologies can be used to enhance compound solubility, dissolution rate, and “to a certain degree, permeability to the gastrointestinal (GI) tract membrane.” ​With these enhancements, a drug that may not be water-soluble can be developed into a more bio-accessible drug.

Compounds with low solubility, stability, short half-life or low bioavailability can benefit the most from the applications of nanotech.

According to Huang, CDMOs can use nanotechnologies to improve a drug’s chance of clinical success by enhancing its bioavailability in animal and human testing.

He also stated that nanotechnologies may be able to reduce development timelines and speed up the introduction of patent opportunities.

Related news

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars